期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

树突状细胞肿瘤疫苗用于胃癌免疫治疗的新进展 被引量：1

The Progress about Immunotherapy of Gastric Carcinoma Using Dendritic Cell Tumor Vaccines
暂未订购
导出
摘要 树突状细胞(DCs)即是体内最有效的专业抗原提呈细胞,也是抗原特异性免疫应答的始动者,具有摄取、加工、递呈抗原至T淋巴细胞的能力,表达高水平的MHCⅠ、Ⅱ和CD80、CD86等共刺激分子,在免疫应答中起关键作用。以DCs为基础的各种疫苗在胃癌免疫治疗中取得了很大的成就。 Dendritic cells are not only the most effective and professional antigen-presenting cells, but also the initiator of antigen-specific immune responses.They can capture, process and present antigens to T lymphocyte and highly express MHC- Ⅰ,MHC- Ⅱ and many other costimulatory molecules such as CD80 ,CD86 and so on . Dendritic cells play a key role in immune responses. Moreover, various vaccines based on DC-achieved a significant success in gastric cancer immunotherapy.
作者 宁敏曼 王立
机构地区 重庆医科大学附属第一医院消化内科
出处 《医学综述》 2006年第4期200-202,共3页 Medical Recapitulate
关键词 胃肿瘤 树突状细胞 免疫治疗 Stomach neoplasms Dendritic cells Immunotherapy
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献24

  • 1Juan Zhang~1 Jin-Kun Zhang~2 Shao-Hong Zhuo~3 Hai-Bin Chen~2 1 Clinical Laboratory,The First Affiliated Hospital of Shantou University Medical College,Shantou 515041,Guangdong Province,China2 Cancer Pathology Laboratory,Shantou University Medical College,Shantou 515031,Guangdong Province,China3 Department of Gastroenterology,Third Municipal Hospital of Shantou,Shantou 515073,Guangdong Province,China.Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells[J].World Journal of Gastroenterology,2001,7(5):690-694. 被引量：26
  • 2Chapoval AI, Tamada K , Chen L. In vitro growth inhibition of a brad spectrum of tumor cell lines by activated human dendritic cells. Blood,2000,95:2346-2351.
  • 3Morisaki T, Katano M, Ikubo A, et al. Immunosuppressive cytokines(IL-10, TGF-beta) genes expression in human gastric carcinoma tissues. J Surg Oncol, 1996,63:234-239.
  • 4Ishigami S, Natsugoe S, Tokuda K, el al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett,2000,159:103-108.
  • 5Banchereau J, Steinman RM. Dendritic cells and the control of immunity . Nature, 1998,392:245-252.
  • 6Gunzer M, Janich S, Varga G. Dendritic cells and tumor immunity.Semin Immunol,2001,13:291-302.
  • 7Becker Y. Anticancer role of dendritic cells (DC) in human and experimental cancers: a review. Anticancer Res, 1992,12:511-520.
  • 8Lu G, Janjic BM, Janjic J, et al. Innate direct anticancex effector function of human immature dendritic cells: Ⅱ Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosisinducing ligand. J Immunol,2002,168:1831-1839.
  • 9Peiper M, Goedegebuure P S,Eberlein T J. Generation of peptide-speific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells[J]. Surgery,1997 Aug,122(2):235-241.
  • 10Runnels H A, Moore J, Jensen P,et al. A structural transition in class II major histocomatibility complex proteins at mildly acidic pH[J]. J Exp Med,1996,183(1):127-136.

共引文献43

同被引文献15

  • 1Connelly RR,Spirtas R,Myers MH,Percy CL,Fraumeni JF Jr.Demographic patterns for mesothelioma in the United States.J Natl Cancer Inst 1987; 78:1053-1060
  • 2Antman KH,Osteen RT,Klegar KL,Amato DA,Pomfret EA,Larson DA,Corson JM.Early peritoneal mesothelioma:a treatable malignancy.Lancet 1985; 2:977-981
  • 3Deraco M,Santoro N,Carraro O,Inglese MG,Rebuffoni G,Guadagni S,Somers DC,Vaglini M.Peritoneal carcinomatosis:feature of dissemination.A review.Tumori 1999; 85:1-5
  • 4Sugarbaker PH,Welch LS,Mohamed F,Glehen O.A review of peritoneal mesothelioma at the Washington Cancer Institute.Surg Oncol Clin N Am 2003; 12:605-621,xi
  • 5Feldman AL,Libutti SK,Pingpank JF,Bartlett DL,Beresnev TH,Mavroukakis SM,Steinberg SM,Liewehr DJ,Kleiner DE,Alexander HR.Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.J Clin Oncol 2003; 21:4560-4567
  • 6Brigand C,Monneuse O,Mohamed F,Sayag-Beaujard AC,Isaac S,Gilly FN,Glehen O.Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy:results of a prospective study.Ann Surg Oncol 2006; 13:405-412
  • 7Deraco M,Nonaka D,Baratti D,Casali P,Rosai J,Younan R,Salvatore A,Cabras Ad AD,Kusamura S.Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.Ann Surg Oncol 2006; 13:229-237
  • 8Glehen O,Mithieux F,Osinsky D,Beaujard AC,Freyer G,Guertsch P,Francois Y,Peyrat P,Panteix G,Vignal J,Gilly FN.Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis:a phase Ⅱ study.J Clin Oncol 2003; 21:799-806
  • 9van Ruth S,Verwaal VJ,Hart AA,van Slooten GW,Zoetmulder FA.Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy.Anticancer Res 2003; 23:1501-1508
  • 10Jacquet P,Sugarbaker PH.Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.Cancer Treat Res 1996; 82:359-374

引证文献1

二级引证文献2

医学综述
2006年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部